Mutations in CHD2 cause defective association with active chromatin in chronic lymphocytic leukemia

Blood

Volumn 126, Issue 2, 2015, Pages 195-202

  Rodríguez, David ^a   Bretones, Gabriel ^a   Quesada, Víctor ^a   Villamor, Neus ^b   Arango, Javier R ^a   López Guillermo, Armando ^b   Ramsay, Andrew J ^a   Baumann, Tycho ^b   Quirós, Pedro M ^a   Navarro, Alba ^b   Royo, Cristina ^b   Martín Subero, José I ^b   Campo, Elías ^b,c   López Otín, Carlos ^a  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMATIN HELICASE DNA BINDING PROTEIN 2; DNA BINDING PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG; CHD2 PROTEIN, HUMAN; CHROMATIN;

ANIMAL CELL; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CHD2 GENE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; EXOME; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN HEAVY CHAIN GENE; MAJOR CLINICAL STUDY; MALE; MONOCLONAL B CELL LYMPHOCYTOSIS; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; AMINO ACID SEQUENCE; ANIMAL; CELL CULTURE; CHLOROCEBUS AETHIOPS; CHROMATIN; COHORT ANALYSIS; COS 1 CELL LINE; GENETICS; HEK293 CELL LINE; METABOLISM; MOLECULAR GENETICS; MUTATION; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; COHORT STUDIES; COS CELLS; DNA-BINDING PROTEINS; HEK293 CELLS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULAR SEQUENCE DATA; MUTATION; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84937918437     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-10-604959     Document Type: Article

References (50)

1. Gaidano G, Fòa R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest. 2012;122(10):3432-3438.
2. Pekarsky Y, Zanesi N, Croce CM. Molecular basis of CLL. Semin Cancer Biol. 2010;20(6):370-376.
3. Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10(1):37-50.
4. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6): 1848-1854.
5. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-1847.
6. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulinvariable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348(18): 1764-1775.
7. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343(26):1910-1916.
8. Gattei V, Bulian P, Del Principe MI, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood. 2008; 111(2):865-873.
9. Puente XS, Pinyol M, Quesada V, et al. Wholegenome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011; 475(7354):101-105.
10. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2012;44(1):47-52.
11. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: Role of NOTCH1 mutational activation. J Exp Med. 2011;208(7):1389-1401.
12. Quesada V, Ramsay AJ, Lopez-Otin C. Chronic lymphocytic leukemia with SF3B1 mutation. N Engl J Med. 2012;366(26):2530.
13. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26): 2497-2506.
14. Ramsay AJ, Quesada V, Foronda M, et al. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat Genet. 2013;45(5): 526-530.
15. Rodŕ?guez D, Ramsay AJ, Quesada V, et al. Functional analysis of sucrase-isomaltase mutations from chronic lymphocytic leukemia patients. Hum Mol Genet. 2013;22(11): 2273-2282.
16. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152(4): 714-726.
17. Damm F, Mylonas E, Cosson A, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov. 2014;4(9): 1088-1101.
18. Ferreira PG, Jares P, Rico D, et al. Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Res. 2014;24(2):212-226.
19. Kulis M, Heath S, Bibikova M, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 2012;44(11):1236-1242.
20. Marfella CG, Ohkawa Y, Coles AH, Garlick DS, Jones SN, Imbalzano AN. Mutation of the SNF2 family member Chd2 affects mouse development and survival. J Cell Physiol. 2006;209(1):162-171.
21. Nagarajan P, Onami TM, Rajagopalan S, Kania S, Donnell R, Venkatachalam S. Role of chromodomain helicase DNA-binding protein 2 in DNA damage response signaling and tumorigenesis. Oncogene. 2009;28(8): 1053-1062.
22. Karube K, Scarfo L, Campo E, Ghia P. Monoclonal B cell lymphocytosis and "in situ" lymphoma. Semin Cancer Biol. 2014;24:3-14.
23. Hudson TJ, Anderson W, Artez A, et al; International Cancer Genome Consortium. International network of cancer genome projects [published correction appears in Nature. 2010;465 (7300):966]. Nature. 2010;464(7291):993-998.
24. Manders EMM, Verbeek FJ, Aten JA. Measurement of co-localization of objects in dual-colour confocal image. J Microsc Oxford. 1993;169(3):375-382.
25. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550.
26. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739-1740.
27. González-Pérez A, López-Bigas N. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am J Hum Genet. 2011;88(4):440-449.
28. Forbes SA, Bindal N, Bamford S, et al. COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39(suppl 1):D945-D950.
29. Marfella CG, Imbalzano AN. The Chd family of chromatin remodelers. Mutat Res. 2007;618(1-2): 30-40.
30. Murawska M, Brehm A. CHD chromatin remodelers and the transcription cycle. Transcription. 2011;2(6):244-253.
31. Sims RJ III, Millhouse S, Chen CF, et al. Recognition of trimethylated histone H3 lysine 4 facilitates the recruitment of transcription postinitiation factors and pre-mRNA splicing. Mol Cell. 2007;28(4):665-676.
32. Ernst J, Kellis M. Interplay between chromatin state, regulator binding, and regulatory motifs in six human cell types. Genome Res. 2013;23(7): 1142-1154.
33. Flanagan JF, Blus BJ, Kim D, Clines KL, Rastinejad F, Khorasanizadeh S. Molecular implications of evolutionary differences in CHD double chromodomains. J Mol Biol. 2007;369(2): 334-342.
34. Sims RJ III, Chen CF, Santos-Rosa H, Kouzarides T, Patel SS, Reinberg D. Human but not yeast CHD1 binds directly and selectively to histone H3 methylated at lysine 4 via its tandem chromodomains. J Biol Chem. 2005;280(51): 41789-41792.
35. Harada A, Okada S, Konno D, et al. Chd2 interacts with H3.3 to determine myogenic cell fate. EMBO J. 2012;31(13):2994-3007.
36. Kelley DE, Stokes DG, Perry RP. CHD1 interacts with SSRP1 and depends on both its chromodomain and its ATPase/helicase-like domain for proper association with chromatin. Chromosoma. 1999;108(1):10-25.
37. Lamond AI, Spector DL. Nuclear speckles: A model for nuclear organelles. Nat Rev Mol Cell Biol. 2003;4(8):605-612.
38. Jones JA, Byrd JC. How will B-cell-receptortargeted therapies change future CLL therapy? Blood. 2014;123(10):1455-1460.
39. Carvill GL, Heavin SB, Yendle SC, et al. Targeted resequencing in epileptic encephalopathies identifies De novo mutations in CHD2 and SYNGAP1. Nat Genet. 2013;45(7):825-830.
40. Suls A, Jaehn JA, Kecskés A, et al; EuroEPINOMICS RES Consortium. De novo lossof-function mutations in CHD2 cause a feversensitive myoclonic epileptic encephalopathy sharing features with Dravet syndrome. Am J Hum Genet. 2013;93(5):967-975.
41. Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010;17(1):28-40.
42. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127): 1546-1558.
43. Quesada V, Ramsay AJ, Rodŕ?guez D, Puente XS, Campo E, López-Otń C. The genomic landscape of chronic lymphocytic leukemia: Clinical implications. BMC Med. 2013;11:124.
44. Burkhardt L, Fuchs S, Krohn A, et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res. 2013;73(9):2795-2805.
45. Kolla V, Zhuang T, Higashi M, Naraparaju K, Brodeur GM. Role of CHD5 in human cancers: 10 years later. Cancer Res. 2014;74(3):652-658.
46. Cheng Y, Ma Z, Kim BH, et al; Mouse ENCODE Consortium. Principles of regulatory information conservation between mouse and human. Nature. 2014;515(7527):371-375.
47. Liu JC, Ferreira CG, Yusufzai T. Human CHD2 is a chromatin assembly ATPase regulated by its chromo-and DNA-binding domains. J Biol Chem. 2015;290(1):25-34.
48. Ramaswamy V, Williams JS, Robinson KM, Sopko RL, Schultz MC. Global control of histone modification by the anaphase-promoting complex. Mol Cell Biol. 2003;23(24):9136-9149.
49. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110d, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123(22):3390-3397.
50. Mertens D, Stilgenbauer S. Prognostic and predictive factors in patients with chronic lymphocytic leukemia: Relevant in the era of novel treatment approaches? J Clin Oncol. 2014;32(9): 869-872.